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Abstract Next-generation sequencing (NGS) provides an
unprecedented opportunity to assess genetic variation un-
derlying human disease. Here, we compared two NGS
approaches for diagnostic sequencing in inherited arrhyth-
mia syndromes. We compared PCR-based target enrichment
and long-read sequencing (PCR-LR) with in-solution
hybridization-based enrichment and short-read sequencing
(Hyb-SR). The PCR-LR assay comprehensively assessed
five long-QT genes routinely sequenced in diagnostic labo-
ratories and “hot spots” in RYR2. The Hyb-SR assay tar-
geted 49 genes, including those in the PCR-LR assay. The
sensitivity for detection of control variants did not differ
between approaches. In both assays, the major limitation
was upstream target capture, particular in regions of extreme
GC content. These initial experiences with NGS cardiovas-
cular diagnostics achieved up to 89 % sensitivity at a frac-
tion of current costs. In the next iteration of these assays we
anticipate sensitivity above 97 % for all LQT genes. NGS
assays will soon replace conventional sequencing for LQT
diagnostics and molecular pathology.
Keywords Inherited cardiac conditions . Next-generation
sequencing . Molecular diagnosis . Genetics . Ion channels .
Long QTsyndrome
Introduction
Genetic subtypes of inherited cardiac conditions (ICCs), such
as long QT (LQT) syndrome, are associated with distinct
patterns of risk and a molecular diagnosis can be used to direct
clinical management [1–5] and permit cascade screening in
families, which is more effective than clinical screening alone
[6]. However, ICCs are genetically heterogeneous [7] and
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conventional sequencing of ICC genes is expensive, time-
consuming and rarely and inequitably applied in clinical prac-
tise, notwithstanding published guidelines [6].
The maturation of recently developed next generation
sequencing (NGS) technologies provides unprecedented se-
quencing capacity at dramatically lower cost, and NGS has
been implemented by some healthcare providers in the US
and Europe for clinical diagnostics of ICCs (e.g., GeneDx,
USA; Sistemas Genómicos, Spain; Oxford Molecular Ge-
netics, UK). To date there have been no published studies
that address the specific challenges of applying NGS tech-
nologies to inherited arrhythmia syndromes that include
LQT syndrome, Brugada syndrome (BrS) and catecholamin-
ergic polymorphic VT (CPVT).
A major challenge associated with targeted NGS is effi-
cient and specific enrichment of disease genes prior to
sequencing as, unlike Sanger sequencing [8], NGS
approaches have no intrinsic target specificity [9]. To
achieve target enrichment prior to NGS, DNA libraries are
most commonly enriched for sequences of interest by PCR-
or hybridization-based methods. PCR-based methods are
typically multiplexed or parallelised in order to produce
amplicons on a scale appropriate for NGS. Mature parallel
approaches may separate PCR reactions in microdroplets
(e.g., RDT 1000, RainDance Technologies) or microfluidic
chips (e.g., Access Array, Fluidigm) before pooling ampli-
cons. More recently, kits for pooled ultrahigh-multiplex
PCR have been released (e.g., Ion Ampliseq, Life Technol-
ogies). The first generation Access Array is appropriate for
targeted resequencing of small (<25,000 bp) regions: a
library of 48 amplicons can be prepared from each of 48
samples in parallel (2,304 independent PCR reactions) in
less than a day, and with little hands-on time [10]. Hybrid-
isation approaches use specific labelled oligonucleotide
baits to separate DNA containing sequences of interest from
background, either in solution or bound to a microarray
chip. Examples include SeqCap EZ Library (in-solution)
and Sequence Capture Arrays (both Roche NimbleGen),
TruSeq in-solution (Illumina) and the SureSelect in-
solution system (Agilent Technologies). These provide off-
the-shelf solutions to capture the whole exome, and custom-
ized versions for user-defined targets, the SureSelect custom
system having a capacity of up to 6 Mb [11, 12].
NGS platforms are often divided into two categories on the
basis of the length of sequence reads that they produce.
Perhaps the most established long-read platform is the 454
GS FLX (454 Life Sciences, Roche) that produces reads of up
to 1,000 bp. The smaller, table-top GS junior platform (also
Roche) produces 400-bp reads and a total sequencing output
of ~40 Mbp (10-h run). Short-read platforms, such as the
Illumina Genome Analyzer II, Illumina HiSeq 2000
(Illumina), Applied Biosystems SOLiD v4 and SOLiD 5500
series (Life Technologies), typically have a significantly
higher throughput than the long-read platforms, making them
more suitable for sequencing a larger number of genes.
Here we present a comparison of two distinct approaches
for NGS high-throughput diagnostics of genes causing
inherited arrhythmia syndromes: PCR-based target enrich-
ment using the Access Array followed by long-read se-
quencing on the GS junior (PCR-LR) and enrichment by
SureSelect in-solution hybridization with short-read SOLiD
v4 sequencing (Hyb-SR).
Methods
Sample Selection
The Hammersmith and Queen Charlotte’s and Chelsea Re-
search Ethics Committee approved the study. DNA was
obtained from subjects who had given written informed
consent and was provided in accordance with Human Tissue
Act, UK guidelines. DNA was extracted using standard
automated approaches and quality and quantity was
assessed by agarose gel electrophoresis and fluorometry
(Qubit, Life Technologies).
A total of 48 patient samples were sequenced. Of these, 33
were sequenced using both approaches, and 15 using one or
other approach (PCR-LR n012, Hyb-SR n03) (Table S1).
Samples included a number of positive controls with variants
previously identified by Sanger sequencing. Nineteen positive
control variants in KCNQ1, KCNH2 and SCN5A were se-
quenced using both assays for direct comparison (Table 1).
Assay Designs
PCR-LR
Fluidigm’s commercial design and validation service was
used to design 96 amplicons targeting five LQT genes
(KCNQ1, KCNH2, SCN5A, KCNE1 and KCNE2) for which
clinical testing is currently available in the UK, together with a
subset of exons fromRYR2 based on the prioritisation schema
proposed by Medeiros-Domingo et al. [13]. Amplicons
ranged from 248 to 600 bp in length, and extended a variable
distance into adjacent introns to cover exon/intron boundaries.
The 96 amplicons covered 42,023 bp of sequence, of which
16,123 bp was our core protein-coding target, and the remain-
der adjacent intronic sequence and UTR.
Hyb-SR
RNA baits were designed for 49 inherited arrhythmia genes
(Table S2) using Agilent’s eArray platform (https://earray.
chem.agilent.com/earray). Baits targeted all exons of all
Ensembl transcripts of these genes, downloaded from
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Ensemble version 54 [14], including UTRs, a 100-bp over-
hang into adjacent introns, and 2 kb of sequence upstream of
the earliest transcription start site. A total of 16,326 unique
120 mer RNA baits were generated with standard eArray
parameters other than five-fold tiling across the target regions
(eArray parameters: sequencing protocol 0 end-sequencing,
tiling frequency 0 5× for exons and adjacent intronic overlap,
2× for 2 kb upstream sequence, bait length 0 120, standard
repeats 0 off, avoid overlap 0 20, layout strategy 0 centred),
covering a target region of 448,412 bp, including 126,638
protein-coding bases. An overview is provided in Fig. 1.
Library Preparation and Sequencing
The workflow is summarised in Fig. S1, and calculations of
anticipated assay capacity are given in Table S3.
PCR-LR
A total of 96 amplicons were prepared from 45 samples in two
48.48 Access Array IFC chips according to the manufacturer’s
Table 1 Detection of positive control variants in samples sequenced on both platforms
Variant type Disease Gene Variant Sample ID SOLiD PSS 454 PSS SOLiD GATK 454 GATK
SNP LQT SCN5A c.6016C>G 02 Yes Yes Yes Yes
SNP LQT KCNQ1 c.859G>A 02 Yes Yes Yes Yes
SNP LQT KCNH2 c.1744C>T 02 Yes Yes Yes No
SNP LQT KCNQ1 c.1697C>T 04 Yes Yes Yes Yes
Indel LQT KCNH2 c.1152delG 05 Yes No No –
SNP LQT KCNH2 c.1926C>G 06 Yes No No No
Indel LQT KCNH2 c.1152delG 08 Yes No No –
SNP LQT KCNQ1 c.965C>T 10 Yes Yes Yes Yes
Indel LQT KCNQ1 c.1486_1487delCT 11 Yes Yes Yes –
Indel LQT KCNH2 c.2775dupG 12 No No No –
Indel LQT KCNH2 c.1916_1918delTCT 13 Yes Yes Yes –
SNP BrS SCN5A c.2236G>A 14 Yes Yes Yes Yes
Indel LQT KCNQ1 c.796delC 15 Yes No Yes –
SNP LQT KCNQ1 c.569G>A 16 Yes Yes Yes No
SNP LQT KCNQ1 c.1702G>A 17 Yes Yes Yes No
SNP LQT KCNQ1 c.569G>A 18 No Yes No Yes
SNP BrS SCN5A c.6010T>C 27 Yes Yes No No
SNP LQT KCNQ1 c.1075C>T 31 Yes Yes Yes Yes
SNP LQT KCNQ1 c.1781G>A 32 Yes Yes No Yes
Sensitivity (%) All variants 89 74 63 n/a
SNPs 92 92 69 62
Indels 83 33 50 n/a
There is no significant difference in sensitivity between platforms (SOLiD PSS v 454 PSS: p00.375). Comparison of software packages within
platform (including additional control variants sequenced on only one platform, listed in Table S1) demonstrates that PSS is more sensitive (454, p0
0.031; SOLiD, p00.031)
Reference sequences: KCNQ10ENST00000155840, KCNH20ENST00000262186, SCN5A0ENST00000333535. See Methods for variant
calling parameters for each approach
PSS platform specific software, GATK Genome Analysis Toolkit, Indel insertion or deletion, LQT long QT syndrome, BrS Brugada syndrome, n/a
not applicable
49 genes, including 12 LQT
genes and RYR2
Target region:
exons (including UTR)
100bp into introns
2000bp upstream
16326 120mer RNA baits
Target size 440k bp
(127k bp protein coding)
5 LQT genes, plus high yield
exons from RYR2
Target region:
exons (protein coding only)
variable intron coverage
no upstream promotor
96 PCR amplicons
Target size 42k bp
(16k bp protein coding)
Agilent Sure Select Fluidigm Access Array
Fig. 1 Summary of target selection designs for the two target enrich-
ment strategies. LQT long QT syndrome, bp base pairs
96 J. of Cardiovasc. Trans. Res. (2013) 6:94–103
standard protocol. In brief, 50 ng (1 μl) of each sample
was combined with barcode library and PCR mastermix
(Roche FastStart High Fidelity PCR System), and trans-
ferred to the primed Access Array chip. Forward and
reverse tagged target-specific primers for each amplicon
were added, and target regions were amplified with in-
corporation of barcodes and sequencing adaptors in a
single nested PCR. Pooled amplicons from each sample
were harvested, and 2 μl of product per sample from
each chip was pooled, purified and quantified. The
pooled library was prepared for sequencing on the GS
junior using the manufacturer’s protocol. Emulsion PCR
(ePCR) was carried out using a ratio of 0.8 copies per
bead, and 500,000–2,000,000 beads were recovered from
ePCR and sequenced in one run.
Hyb-SR
A total of 36 samples were enriched and barcoded using the
SureSelect system according to the manufacturer’s standard
protocols, in batches of eight (low multiplex) and 24 (high
multiplex). First, 3 μg of DNA in 120 μl of low TE was
sheared, end-repaired and ligated with sequencing adaptors.
Next, 200- to 250-bp fragments were selected using agarose
gel electrophoresis, prior to nick-translation and amplifica-
tion. Then, 500 ng of DNA was then incubated with target-
specific biotinylated RNA baits for 24 h, and the target
DNA captured using streptavidin-coated magnetic beads.
Libraries were quantified by qPCR and pooled. Following
ePCR, libraries were sequenced on the SOLiD v4 using
paired-end sequencing.
Data Analysis
Two analysis pipelines were compared for each NGS plat-
form. In each case the manufacturer’s proprietary platform-
specific variant-calling software was compared against the
freely available and widely used Genome-Analysis Toolkit
(GATK, v1.0.5232) [15].
PCR-LR
GS Amplicon Variant Analyser (AVA, version 2.5p1) was
used as an integrated system for read trimming, de-
multiplexing and variant calling. This software provides
limited user-accessible data on read quality and coverage,
so for comparability against the SOLiD data a custom pipe-
line was also used. In this pipeline reads were de-
multiplexed, trimmed, and converted to FASTQ format us-
ing SffTools (454 Sequencing System Software, v2.5p1)
and sff2fastq (http://github.com/indraniel/sff2fastq). Short
and long reads (cut-off 0 100 bp) were aligned separately
to the human reference genome (hg19) using BWA-short
and BWA-SW, respectively [16, 17] and aligned reads
recombined. Alignment metrics were calculated with Picard
v1.37 (http://picard.sourceforge.net). Coverage data were
obtained using SAMtools v0.1.12-10 (r896) [18], Picard, Bed-
Tools [19] and the GATK Callable Loci Walker [20]. Bases
covered by at least four reads with a mapping quality ≥20
and base quality ≥10 were denoted “callable”, i.e., ade-
quately covered for variant calling with recommended
GATK parameters. High quality aligned reads were passed
to GATK for SNP calling (as GATK does not support indel
calling on 454 data) using recommended parameters and
filters (min_base_quality_score010; min_mapping_quali-
ty_score020; stand_call_conf010.0; stand_emit_conf0
30.0; minIndelCnt04. Downstream filters: QUAL<30,
QD<5, HRun>5; DP<4). Putative variants identified by
AVA were accepted if present on both strands with total
coverage of at least four reads.
Hyb-SR
SOLiD reads were de-multiplexed and aligned in colour space
using SOLiD BioScope v1.3. Duplicate reads were marked
using Picard, and alignment and coverage metrics obtained as
previously described for the GS junior data. Variant calling
was carried out using GATK and BioScope using recommen-
ded parameters (GATK parameters as above. Lifescope: het/
hom.min.coverage03; het.min.allele.ratio00.15; read-
s.min.mapping.qv020; het/hom.min.nonref.color.qv010;
call.stringency0medium; small.indel.min.num.evid04;
small.indel.min.best.mapping.quality020. Downstream filter:
diBayes p<0.05).
Target enrichment factor was calculated as Enrichment
Factor ¼ Reads on target=Total mapped readsTarget size=Genome size . Here, “target” refers to
all protein-coding bases only, though amplicons/baits were
designed to capture adjacent regions.
For comparability, the depth of coverage, proportion of
bases meeting variant calling criteria, and the evenness of
coverage were calculated for the protein-coding portions of
the six genes common to both assays. The same metrics
were also calculated for all genes in the Hyb-SR assay.
Evenness was calculated according to the method de-
scribed by Mokry et al. [21], implemented with the R
statistical package (http://www.r-project.org/) using a cus-
tom script. This yields a score in the range 0–1, with 1
indicating perfectly uniform coverage. The correlation be-
tween sequencing depth and callable bases was assessed
using Spearman’s rho, implemented in R (stats package,
version 2.13.1).
Variants were functionally annotated using the Ensembl
API (version 63) [22] and HGMD Professional version
2011.1 [23]. The number of positive-control variants detected
by each platform and each analysis pipeline was compared
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using theMcNemar exact test, implemented with the exact2x2
package in R [24].
Results
Target Enrichment and Sequencing Metrics
The sequencing output and enrichment statistics are sum-
marized in Table S4. PCR-LR had high target specificity,
with 89 % of uniquely mapped reads on target (mean en-
richment factor0170,900). The reads that did not map were
almost exclusively short DNA fragments: 22 % of reads
were short (<100 bp), of which <1 % mapped, whereas
99.97 % of longer reads mapped. For Hyb-SR, up to 25 %
of mapped reads were on target, which is as expected for in
solution hybridization with a relatively small target size.
[12] Of these on target reads 49 % were flagged as dupli-
cates prior to variant calling at low sequencing depth, rising
to 84 % with increased sequencing. Mean enrichment factor
was 3,505 at high multiplex, and 5,864 at low multiplex.
Coverage of Targeted Genes
We compared assay performance using the six genes se-
quenced using both approaches (KCNQ1, KCNH2,
SCN5A, KCNE1, KCNE2 and RYR2), and determined
what proportion of each gene was covered adequately to
identify variants (“callable”). Target capture and sequencing
depth both contribute to determine whether a base is call-
able, so to dissect these the effect of sequencing depth was
first investigated. We demonstrated a strong correlation
between bases callable and mean sequencing depth across
samples (Hyb-SR, ρ00.95, p<2.2×10−16; PCR-LR,
ρ00.81, p<2.2×10−16), but with better performance of the
PCR-LR at lower coverage (Fig. 2). In each case the rela-
tionship is approximately linear at low sequencing depth,
and then approaches a plateau when all of the bases captured
by upstream enrichment are covered at this minimum depth.
Hyb-SR at low multiplex has reached this plateau, and
therefore represents the best possible coverage achievable
by this target enrichment design. Hyb-SR at high multiplex
has not yet reached the plateau: in clinical application mean
sequencing depth would need to be increased to 250–300×
ensure maximum coverage. As PCR-LR is not sequenced at
sufficient depth to eliminate this factor, a high coverage
virtual sample was generated by pooling reads from many
samples (~90 k reads, yielding 663× coverage). This pooled
sample has been used to compare target capture under
optimum conditions.
The depth of coverage of the target region was higher
using Hyb-SR, but the regions of these six genes sequenced
to sufficient depth to confidently identify variants were
similar for both approaches (Table 2, six genes, both assays;
Table S2, 49 genes in Hyb-SR assay). Of note, the perfor-
mance of the Hyb-SR across the six LQT genes was not as
good as the average performance of Hyb-SR across all 49
genes in this comprehensive assay (Table 3), perhaps reflect-
ing the high GC content of some LQT genes.
Visual representation of the coverage of the three princi-
pal LQT genes (Fig. 3) revealed the variable capture perfor-
mance across the genes. Regions missed tended to have
extreme GC content (Fig. 4), with many of these regions
common to both platforms. PCR-LR is sensitive to both
extremes of GC, while Hyb-SR appears robust to low GC
content. A previous study has shown that this is a distinctive
feature of the SureSelect system, which outperforms other
hybridisation-based enrichment systems in regions of low
GC content [25]. Qualitatively, Hyb-SR yields highly vari-
able coverage across the target, while PCR-LR yields even
coverage within amplicons, but significant inter-amplicon
variability and some areas of high coverage where two
amplicons overlap. Quantitatively, PCR-LR coverage is no
more even than Hyb-SR coverage.
Fig. 2 For a given target enrichment design, the percentage of bases
reaching variant-calling criteria increases with increasing sequencing
depth. For each sample, the percentage of target bases callable is
plotted against the mean sequencing depth achieved for that sample.
The Hyb-SR reached saturation when run with low multiplex,
suggesting that a further increase in sequencing depth would not
improve coverage. PCR-LR has not reached saturation: the dotted line
shows maximum achievable coverage with a simulated sample gener-
ated by pooling reads from all samples, equivalent to ×660 depth
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Variant Detection
Using the proprietary variant-calling pipeline for each plat-
form there is no significant difference in detection of 19
known variants between platforms (Table 1; Hyb-SR 89 %,
PCR-LR 74 %, p00.375). In general, variants that were not
detected were in areas of poor coverage, suggesting that
they were not captured adequately by the target-
enrichment strategies, not sequenced adequately (due to
emulsion PCR or sequencing biases), or not uniquely
aligned during sequence alignment. The only variant to be
missed by both variant-calling approaches on both platforms
(KCNH2 c.2775dupG) fell in a region with 79 % GC
yielding no coverage on PCR-LR and two reads on Hyb-
SR. Other missed variants were largely attributable to either
low/no coverage, or coverage-related variant-calling filters in
GATK (e.g., Quality by Depth). It is notable that the variants
missed were in regions of higher GC content than those
consistently detected (GC 65±3 % vs. 59±2 %, p00.014).
For each approach we compared GATK against platform-
specific software (BioScope, SOLiD; AVA, GS junior). In
both cases, there were no positive control variants that were
detected by GATK and missed by the platform-specific
software, while a modest number were detected by
platform-specific software and missed by GATK
(Table S5). Platform-specific software is statistically more
sensitive than GATK (454, p00.031; SOLiD, p00.031).
Cost and Time Comparisons
Comparative costs for consumables alone are shown in
Table 4. Both NGS approaches represent a significant cost
saving over conventional sequencing, although these figures
do not include capital, maintenance, or informatics costs for
either NGS or conventional capillary sequencing. A single
high-throughput capillary sequencer could, in theory, se-
quence five LQT genes (66 amplicons) in 17 samples in
1 day, with significant additional time required for upstream
PCR and sample preparation. PCR-LR takes 2 days for
target enrichment and sequencing of 48 samples. Time
estimates for Hyb-SR depend on whether upstream automa-
tion is used, with the sequencing itself taking up to 2 weeks.
Discussion
NGS is a mature technology for clinical diagnostics and prom-
ises comprehensive genetic assessment at low cost. While the
initial LQTassays described here will require optimisation prior
to clinical application, some targeted genes are already fully
sequenced (Table 2). We point out that while conventional
Table 2 Percentage of bases covered sufficiently for variant calling by
gene, for each assay (median across samples). For Hyb-SR, results are
shown from a low multiplex run with high sequencing depth, approxi-
mating to optimal performance for this assay. The PCR-LR run was
relatively under-sequenced, so increased sequencing depth was simulated
by pooling reads from many samples. PCR-LR would yield better cov-
erage with increased sequencing depth (e.g., fewer multiplexed samples)
Gene Syndrome Hyb-SR
(low multiplex)
PCR-LR PCR-LR pooled
(high-coverage)
KCNQ1 LQT1 83.4 80.9 80.9
KCNH2 LQT2 78.2 80.8 89.2
SCN5A LQT3 99.9 89.2 97.8
KCNE1 LQT5 100.0 100.0 100.0
KCNE2 LQT6 100.0 100.0 100.0
aRYR2 CPVT 100.0 87.8 89.2
aWith respect to the RYR2 exons targeted by both assays. Performance
across the whole RYR2 gene for the Hyb-SR is shown in Table S2
Table 3 Target enrichment: coverage of targeted bases
Assay Bases covered (%) Mean (median) sequencing depth Evenness
≥1× ≥5× ≥10× Callablea
Performance across shared target (6 genes; 16,123 bp)
Hyb-SR low multiplex 95.6 93.8 92.6 93.3 163 (177) 0.79
Hyb-SR high multiplex 94.0 90.0 87.4 85.4 55.8 (54.5) 0.72
PCR-LR 90.5 82.5 68.4 85.6 14.4 (14) 0.72
PCR-LR pooled (simulated high coverage) 93.2 93.2 93.2 93.2 663 (687) 0.77
Performance across whole target (49 genes; 126,638 bp)
Hyb-SR low multiplex 98.3 97.3 96.6 97.0 167 (176) 0.82
Hyb-SR high multiplex 97.4 95.2 93.5 92.0 68.6 (73) 0.79
Data is shown for two Hyb-SR runs (at low and high multiplexes), PCR-LR, and a simulated high coverage PCR-LR sample. Hyb-SR at low
multiplex and PCR-LR pooled give an indication of the maximum performance of each target enrichment design with sufficiently deep sequencing
a Callable0percentage of bases meeting variant calling criteria, assessed using GATK callable loci walker
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sequencing (or mutation scanning) has a notional sensitivity for
the detection of SNPs and small indels approaching 100%, this
is only the case if sequencing is applied to all exons of all genes.
In practice, this is seldom the case. Most often analysis is
limited to a subset of disease genes, or a limited number of
exons of a gene (http://www.genetests.org/). It remains un-
known, for example, how the overall diagnostic yield of a test
that detects 90 % of variants in 50 genes might compare with a
test detecting 99 % of variants in five genes. At the same time,
background noise increases as the size of the diagnostic gene
panel increases, making the discrimination of pathogenic and
benign variants more challenging.
Conventional sequencing is not the gold standard for detec-
tion of other forms of pathogenic variation, and conventional
diagnostics is evolving to incorporate new technologies, such
as multiplex ligation-dependent probe amplification for copy
number variation detection. Methods to identify large structural
variants and copy number variants directly from NGS are now
available [26]: these are more likely to be applicable to
hyridisation-based targeted enrichment.
Improving Assay Performance
To improve the performance of the NGS assays described here
target capture clearly requires optimisation, though initial
results are comparable to those previously reported for a
cardiomyopathy screen based on on-array hybridisation and
SOLiD sequencing [27] (91 % coverage at 10×, enrichment
factor 2,169). Sub-optimal target enrichment may have arisen
at several stages. A minority of regions were excluded from
Fig. 3 Coverage of the three
genes most commonly causing
long QT syndrome. Sequencing
depth is plotted base by base
across the protein-coding por-
tions of three genes for a single
sample sequenced on both plat-
forms. Coverage varies widely
for the Hyb-SR approach. PCR-
LR yields more even coverage
within amplicons, but there
remains significant inter-
amplicon variability. The first
exons of KCNQ1 and KCNH2
are poorly captured by both
techniques. The proportion
covered sufficiently for variant
calling ranges from 78 %
(KCNH2, Hyb-SR) to 100 %
Fig. 4 Target enrichment is strongly dependent on GC content. The
distribution of GC content for the target region is shown, together with
the GC content of bases consistently missed across all samples for each
platform. Regions missed by Hyb-SR have a high GC content, while
regions missed by PCR-LR may have a GC content at either extreme
Table 4 Consumables costs for target enrichment and sequencing
technologies
Technology Cost per sample
Conventional Sanger sequencinga (5 genes) £475 ($736, €594)
Access Array target enrichmentb (5½ genes) £10
GS junior sequencingc £25
PCR-LR Total £35 ($54, €44)
SureSelect target enrichmentd (49 genes) £90
SOLiD v4 sequencinge £35
Hyb-SR total £125 ($194, €156)
a PCR and bidirectional sequencing of 66 amplicons (5 LQT genes), at
£3.60 per amplicon
b Price excludes outsourcing of design and validation of primers
(0£3450 for 48 amplicons)
c Forty-eight samples on one GS junior run
d Includes design cost, and assumes bulk purchase of 1,000 captures
e Thirty-two samples in one quarter of a SOLiD slide, 50+35 paired-
end sequencing
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the design due to strict amplicon or bait design parameters
(e.g., noAccess Array amplicon was successfully designed for
KCNQ1 exon 1; Fig. 3). Although not quantifiable, failure in
bait or primer design during production may also have oc-
curred. Variability in assay performance is likely primarily a
function of efficiency of hybridisation and/or PCR, which are
known to be sensitive to factors such as GC content (Fig. 4)
[12]. Indeed, we have observed some improvement in the
Access Array performance using an alternative GC-robust
PCR approach (data not shown).
Assay performance could be improved by increasing
sequencing depth per sample, pushing borderline regions
above variant calling threshold (Fig. 2). However, this is
inefficient if coverage is uneven, as sequencing of efficient-
ly captured regions also increases. Redistribution of se-
quencing through more even capture would be preferable.
PCR-based enrichment is said to produce even coverage
[10], but our data show no advantage over hybridisation-
based enrichment. The majority of bases not callable in the
PCR-LR assay reflected no coverage, rather than low cov-
erage, while the converse is true for Hyb-SR. This suggests
that assay rebalancing through bait re-distribution may be
most relevant for hybridisation-based enrichment, while
amplicon performance tends towards all-or-none for PCR.
Variant Calling and Detection
We found that platform-specific proprietary variant calling
software has a higher sensitivity than GATK, a widely
accepted open-source package. Although GATK is
platform-independent, it has developed alongside projects
such as the 1000 genome project [28], for which most data
has come from the Illumina platform and at low coverage.
The Bioscope software has been written specifically to take
advantage of the colour-space base encoding on the SOLiD.
The AVA software, whilst more sensitive than GATK, does
not produce quality values for variant calls, is less transparent
and has few customisable parameters. Overall, for an initial
experiment, both platforms performed appropriately in detect-
ing previously identified causative mutations (Table 1) with a
trend to better performance with Hyb-SR.
Although this study was not powered to compare the
detection of different variant classes (insertions, deletions
and duplications vs. SNPs), it has previously been noted that
insertions and deletions are more difficult to detect in NGS
data [9, 27]. We observed that Hyb-SR detects six out of
seven such variants, while PCR-LR detects two of six var-
iants (Table 1 and Table S1). This warrants further investi-
gation, particularly given the known sensitivity of 454
sequencing to homopolymer regions [9]. The SureSelect
system has previously been reported to be more sensitive
to small indels at low coverage than other hybridisation-
based target-enrichment systems [25].
The Hyb-SR assay is comprehensive, including genes that
are rare causes of LQT (not normally tested clinically) and genes
for other arrhythmia syndromes. Alongside our core LQT/BrS
comparator samples for the study we sequenced a number of
additional samples with other arrhythmia phenotypes to explore
this. Two positive control variants from patients with arrhyth-
mogenic right ventricular cardiomyopathy were included, and
Table 5 A comparative over-
view of the two approaches
assessed in this study
Hyb-SR hybridisation-based tar-
get enrichment (SureSelect) and
short-read sequencing (SOLiD),
PCR-LR PCR-based target en-
richment (Access Array) and
long-read sequencing (454 GS
junior)
PCR-LR Hyb-SR
Assay capacity Modest (~ 24 kb) Comprehensive (~6 Mb for custom
designs)
Target enrichment cost Low (~£10 per sample) Higher (~£100 per sample)
Sequencing cost Hyb-SR cheaper per unit of
sequencing, but cost per sample
comparable given PCR-LR likely to
be used for more focused assay
Turnaround time ~2 days ~2 weeks
User-friendly automated target-
enrichment
More complex library preparation.
Automation available
Technical considerations High specificity/enrichment factor Lower specificity/enrichment factor
Sensitive to extremes of GC Sensitive to high GC, relatively
robust to low GC
Low sequencing depth required for
given coverage
Higher sequencing depth required
Platform-specific software less
transparent
Platform-specific software easily
integrates with other bioinformatic
packages
Indel calling not available in GATK GATK a fully featured alternative
PCR amplification prevents CNV
detection
CNV detection likely to become
available
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both correctly identified (Table S1). Additional findings includ-
ed a novel SNP in an essential splice donor site in ANK2 in a
patient with otherwise unexplained LQT syndrome
(ENST00000357077.4:c.1485+2T>C); a non-synonymous
SNP in ANK2 that has been previously reported to cause LQT
[29], now found in a molecular autopsy sample from a sudden
unexplained death victim (ENST00000357077.4:c.10708G>A;
ENSP00000349588.4:p.Glu3570Lys); and a novel variant at an
essential splice site in RYR2 in a patient with unexplained
ARVC (ENST00000366574.2:c.10725+1G>T). Although ap-
propriate caution is required when interpreting sequencing data
from large panel of genes, these illustrate the potential benefits
of a single comprehensive assay.
Assigning Pathogenicity to Variants
The major challenge in genetic diagnosis is distinguishing
between pathogenic variants and benign rare variants. Al-
though projects such as the 1000 Genomes project [28] and
UK10K (http://www.uk10k.org/) will improve our knowl-
edge of common and less common variants, many rare
variants will not be catalogued. Moreover, variants identi-
fied in these projects cannot all be assumed to be benign, as
cohorts with incomplete phenotypic information may in-
clude some patients carrying unrecognised disease-causing
variants, and variants that are insufficient to cause disease in
isolation may still contribute to oligogenic inherited disease.
One solution is to sequence large multi-racial control
cohorts that have very accurate cardiovascular phenotypes
— a prospect that is both achievable and affordable using
the assays described here.
Summary
Table 5 gives a comparative overview of the two approaches.
PCR-LR has the advantages of low cost, rapid turnaround,
and relative ease of use. Although our assay will require at
least one cycle of iterative improvement, we anticipate over
97 % of bases will be callable for all LQT genes in our next
design (based on our experience in optimisation of other NGS
assays). In addition, Fluidigm’s recent PCR multiplexing pro-
tocol for the Access Array [30] markedly increases assay
capacity and this combined with the higher throughput desk-
top sequencers (MiSeq, Illumina; Ion Torrent, Life Technolo-
gies) promises a rapid and comprehensive sudden death assay.
The Hyb-SR assay we developed is cheaper than Sanger
sequencing, although more expensive and time consuming
than PCR-LR. The major advantage of the Hyb-SR assay is
its capacity, with a much more comprehensive panel of po-
tentially causative genes. There is also the potential for sub-
stantial economies of scale with Hyb-PCR as a single assay
covering genes for many (or all) ICCs could be run as a single
test with very high throughput. By contrast, PCR-LR on the
GS Junior platform would require a separate assay for each
syndrome, each requiring optimization and validation.
This study also illustrates that target capture performance
varies for different genes, and some LQT genes are difficult
to capture. Sensitivity and specificity vary with platform and
software choices. Early adopters of NGS diagnostics must
ensure that measures of sensitivity for each gene are clearly
reported in both advertising and genetic test reports.
The challenges of interpreting variants of unknown sig-
nificance are substantial, but deep sequencing of well-
phenotyped normal cohorts using these comprehensive
high-throughput assays will powerfully inform our interpre-
tation. In a short time, NGS will transform the genetic
testing strategy for LQT, sudden arrhythmic death and other
molecular pathologies and change the landscape of genomic
cardiovascular medicine beyond recognition.
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